

PCT09

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/856,199

DATE: 10/11/2001
 TIME: 09:53:19

Input Set : A:\0020-4867P.ST25.txt
 Output Set: N:\CRF3\10112001\I856199.raw

ENTERED

3 <110> APPLICANT: HIRASHIMA, Masaki et al.
 5 <120> TITLE OF INVENTION: PEPTIDE FRAGMENTS HAVING CELL DEATH-INHIBITORY ACTIVITY
 7 <130> FILE REFERENCE: 0020-4867P
 9 <140> CURRENT APPLICATION NUMBER: 09/856,199
 10 <141> CURRENT FILING DATE: 2001-05-18
 12 <160> NUMBER OF SEQ ID NOS: 7
 14 <170> SOFTWARE: PatentIn version 3.1
 16 <210> SEQ ID NO: 1
 17 <211> LENGTH: 29
 18 <212> TYPE: PRT
 19 <213> ORGANISM: Human plasma
 21 <220> FEATURE:
 22 <221> NAME/KEY: misc_feature
 23 <222> LOCATION: (1)..(29)
 24 <223> OTHER INFORMATION: Xaa represents selenocysteine
 27 <400> SEQUENCE: 1
 29 Lys Arg Cys Ile Asn Gln Leu Leu Cys Lys Leu Pro Thr Asp Ser Glu
 30 1 5 10 15
 W--> 33 Leu Ala Pro Arg Ser Xaa Cys Cys His Cys Arg His Leu OK
 34 20 25
 37 <210> SEQ ID NO: 2
 38 <211> LENGTH: 28
 39 <212> TYPE: PRT
 40 <213> ORGANISM: Human plasma
 42 <220> FEATURE:
 43 <221> NAME/KEY: misc_feature
 44 <222> LOCATION: (1)..(28)
 45 <223> OTHER INFORMATION: Xaa represents selenocysteine
 48 <400> SEQUENCE: 2
 W--> 50 Thr Gly Ser Ala Ile Thr Xaa Gln Cys Lys Glu Asn Leu Pro Ser Leu
 51 1 5 10 15
 W--> 54 Cys Ser Xaa Gln Gly Leu Arg Ala Glu Glu Asn Ile OK
 55 20 25
 58 <210> SEQ ID NO: 3
 59 <211> LENGTH: 103
 60 <212> TYPE: PRT
 61 <213> ORGANISM: Human plasma
 63 <220> FEATURE:
 64 <221> NAME/KEY: misc_feature
 65 <222> LOCATION: (1)..(103)
 66 <223> OTHER INFORMATION: Xaa represents selenocysteine
 69 <400> SEQUENCE: 3
 71 Lys Arg Cys Ile Asn Gln Leu Leu Cys Lys Leu Pro Thr Asp Ser Glu
 72 1 5 10 15
 W--> 75 Leu Ala Pro Arg Ser Xaa Cys Cys His Cys Arg His Leu Ile Phe Glu OK
 76 20 25 30
 W--> 79 Lys Thr Gly Ser Ala Ile Thr Xaa Gln Cys Lys Glu Asn Leu Pro Ser

RAW SEQUENCE LISTING

DATE: 10/11/2001

PATENT APPLICATION: US/09/856,199

TIME: 09:53:19

Input Set : A:\0020-4867P.ST25.txt

Output Set: N:\CRF3\10112001\I856199.raw

```

      80          35          40          45
W--> 83 Leu Cys Ser Xaa Gln Gly Leu Arg Ala Glu Glu Asn Ile Thr Glu Ser
      84          50          55          60
W--> 87 Cys Gln Xaa Arg Leu Pro Pro Ala Ala Xaa Gln Ile Ser Gln Gln Leu
      88 65          70          75          80
W--> 91 Ile Pro Thr Glu Ala Ser Ala Ser Xaa Arg Xaa Lys Asn Gln Ala Lys
      92          85          90          95
W--> 95 Lys Xaa Glu Xaa Pro Ser Asn
      96          100
99 <210> SEQ ID NO: 4
100 <211> LENGTH: 20
101 <212> TYPE: PRT
102 <213> ORGANISM: Human plasma
104 <400> SEQUENCE: 4
106 Lys Arg Cys Ile Asn Gln Leu Leu Cys Lys Leu Pro Thr Asp Ser Glu
107 1          5          10          15
110 Leu Ala Pro Arg
111          20
114 <210> SEQ ID NO: 5
115 <211> LENGTH: 21
116 <212> TYPE: PRT
117 <213> ORGANISM: Human plasma
119 <400> SEQUENCE: 5
121 Lys Arg Cys Ile Asn Gln Leu Leu Cys Lys Leu Pro Thr Asp Ser Glu
122 1          5          10          15
125 Leu Ala Pro Arg Ser
126          20
129 <210> SEQ ID NO: 6
130 <211> LENGTH: 381
131 <212> TYPE: PRT
132 <213> ORGANISM: Human plasma
134 <220> FEATURE:
135 <221> NAME/KEY: misc_feature
136 <222> LOCATION: (1)..(381)
137 <223> OTHER INFORMATION: Xaa represents selenocysteine
140 <220> FEATURE:
141 <221> NAME/KEY: SIGNAL
142 <222> LOCATION: (1)..(19)
143 <223> OTHER INFORMATION: Signal sequence
146 <400> SEQUENCE: 6
148 Met Trp Arg Ser Leu Gly Leu Ala Leu Ala Leu Cys Leu Leu Pro Ser
149 1          5          10          15
152 Gly Gly Thr Glu Ser Gln Asp Gln Ser Ser Leu Cys Lys Gln Pro Pro
153          20          25          30
156 Ala Trp Ser Ile Arg Asp Gln Asp Pro Met Leu Asn Ser Asn Gly Ser
157          35          40          45
W--> 160 Val Thr Val Val Ala Leu Leu Gln Ala Ser Xaa Tyr Leu Cys Ile Ile
161          50          55          60
164 Glu Ala Ser Lys Leu Glu Asp Leu Arg Val Lys Leu Lys Lys Glu Gly

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/856,199

DATE: 10/11/2001

TIME: 09:53:19

Input Set : A:\0020-4867P.ST25.txt

Output Set: N:\CRF3\10112001\I856199.raw

```

165 65              70              75              80
168 Tyr Ser Asn Ile Ser Tyr Ile Val Val Asn His Gln Gly Ile Ser Ser
169              85              90              95
172 Arg Leu Lys Tyr Thr His Leu Lys Asn Lys Val Ser Glu His Ile Pro
173              100              105              110
176 Val Tyr Gln Gln Glu Glu Asn Gln Thr Asp Val Trp Thr Leu Leu Asn
177              115              120              125
180 Gly Ser Lys Asp Asp Phe Leu Ile Tyr Asp Arg Cys Gly Arg Leu Val
181              130              135              140
184 Tyr His Leu Gly Leu Pro Phe Ser Phe Leu Thr Phe Pro Tyr Val Glu
185 145              150              155              160
188 Glu Ala Ile Lys Ile Ala Tyr Cys Glu Lys Lys Cys Gly Asn Cys Ser
189              165              170              175
192 Leu Thr Thr Leu Lys Asp Glu Asp Phe Cys Lys Arg Val Ser Leu Ala
193              180              185              190
196 Thr Val Asp Lys Thr Val Glu Thr Pro Ser Pro His Tyr His His Glu
197              195              200              205
200 His His His Asn His Gly His Gln His Leu Gly Ser Ser Glu Leu Ser
201              210              215              220
204 Glu Asn Gln Gln Pro Gly Ala Pro Asn Ala Pro Thr His Pro Ala Pro
205 225              230              235              240
208 Pro Gly Leu His His His His Lys His Lys Gly Gln His Arg Gln Gly
209              245              250              255
212 His Pro Glu Asn Arg Asp Met Pro Ala Ser Glu Asp Leu Gln Asp Leu
213              260              265              270
216 Gln Lys Lys Leu Cys Arg Lys Arg Cys Ile Asn Gln Leu Leu Cys Lys
217              275              280              285
W--> 220 Leu Pro Thr Asp Ser Glu Leu Ala Pro Arg Ser Xaa Cys Cys His Cys
221              290              295              300
W--> 224 Arg His Leu Ile Phe Glu Lys Thr Gly Ser Ala Ile Thr Xaa Gln Cys
225 305              310              315              320
W--> 228 Lys Glu Asn Leu Pro Ser Leu Cys Ser Xaa Gln Gly Leu Arg Ala Glu
229              325              330              335
W--> 232 Glu Asn Ile Thr Glu Ser Cys Gln Xaa Arg Leu Pro Pro Ala Ala Xaa
233              340              345              350
W--> 236 Gln Ile Ser Gln Gln Leu Ile Pro Thr Glu Ala Ser Ala Ser Xaa Arg
237              355              360              365
W--> 240 Xaa Lys Asn Gln Ala Lys Lys Xaa Glu Xaa Pro Ser Asn OK
241              370              375              380
244 <210> SEQ ID NO: 7
245 <211> LENGTH: 20
246 <212> TYPE: PRT
247 <213> ORGANISM: Human plasma
249 <220> FEATURE:
250 <221> NAME/KEY: misc_feature
251 <222> LOCATION: (1)..(20) OK
252 <223> OTHER INFORMATION: Xaa represents selenocysteine
255 <400> SEQUENCE: 7
W--> 257 Thr Gly Ser Ala Ile Thr Xaa Gln Cys Lys Glu Asn Leu Pro Ser Leu

```

DATE: 10/11/2001

TIME: 09:53:19

Input Set : A:\0020-4867P.ST25.txt

Output Set: N:\CRF3\10112001\I856199.raw

258 1 5 10 15
W--> 261 Cys Ser Xaa Gln
262 20 *one*

SECRET

VERIFICATION SUMMARY

DATE: 10/11/2001

PATENT APPLICATION: US/09/856,199

TIME: 09:53:20

Input Set : A:\0020-4867P.ST25.txt

Output Set: N:\CRF3\10112001\I856199.raw

L:33 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:54 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:75 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:79 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:87 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:91 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:95 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:220 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:224 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:232 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:236 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:240 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:257 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:261 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7